NGS in advanced breast cancer: exploring recent clinical advancements

Back to Webinars

Original Webinar Date: 03/30/2023

NGS in advanced breast cancer: exploring recent clinical advancements

Learn more about breast cancer management with NGS. We explore the potential utility of complementary solid tumor and liquid biopsy testing in informing treatment decisions, as well as patient management strategies in the post CDK4/6 inhibitor therapy setting.

Speakers Calvin Chao, MD
SVP of Medical Affairs, Tempus

Cynthia Ma, MD, PhD
Professor of Medicine, Washington University in St. Louis, Siteman Cancer Center

Massimo Cristofanilli, MD, FACP
Chief, Breast Medical Oncology, Sandra Edward Meyer Cancer Center at Weill Cornell Medicine

<span data-mce-type="bookmark" style="display: inline-block; width: 0px; overflow: hidden; line-height: 0;" class="mce_SELRES_start"></span><span data-mce-type="bookmark" style="display: inline-block; width: 0px; overflow: hidden; line-height: 0;" class="mce_SELRES_start"></span><span data-mce-type="bookmark" style="display: inline-block; width: 0px; overflow: hidden; line-height: 0;" class="mce_SELRES_start"></span><span data-mce-type="bookmark" style="display: inline-block; width: 0px; overflow: hidden; line-height: 0;" class="mce_SELRES_start"></span><span data-mce-type="bookmark" style="display: inline-block; width: 0px; overflow: hidden; line-height: 0;" class="mce_SELRES_start"></span><span data-mce-type="bookmark" style="display: inline-block; width: 0px; overflow: hidden; line-height: 0;" class="mce_SELRES_start"></span><span data-mce-type="bookmark" style="display: inline-block; width: 0px; overflow: hidden; line-height: 0;" class="mce_SELRES_start"><span data-mce-type="bookmark" style="display: inline-block; width: 0px; overflow: hidden; line-height: 0;" class="mce_SELRES_start"></span><span data-mce-type="bookmark" style="display: inline-block; width: 0px; overflow: hidden; line-height: 0;" class="mce_SELRES_start"></span></span>

Related Content

View more

04/16/2024

Reduce time to launch with Tempus and multimodal data

How AstraZeneca simplified its approach to TROPION-Lung01 and drove down time to launch.
Read more
04/16/2024

Make quicker decisions by simulating and contextualizing data with Tempus

Mirati leverages Tempus data to revise its KRAS strategy and refine its patient selection approach
Read more
04/16/2024

Enhance your clinical development process with Tempus’ CDx platform

Learn how A2 Biotherapeutics is making progress on a breakthrough cell therapy using HLA-LOH (human leukocyte antigen-loss of heterozygosity) as a biomarker, using Tempus’ comprehensive immunotherapy platform.
Read more